These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31040850)

  • 41. LBSapSal-vaccinated dogs exhibit increased circulating T-lymphocyte subsets (CD4⁺ and CD8⁺) as well as a reduction of parasitism after challenge with Leishmania infantum plus salivary gland of Lutzomyia longipalpis.
    Aguiar-Soares RD; Roatt BM; Ker HG; Moreira Nd; Mathias FA; Cardoso JM; Gontijo NF; Bruna-Romero O; Teixeira-Carvalho A; Martins-Filho OA; Corrêa-Oliveira R; Giunchetti RC; Reis AB
    Parasit Vectors; 2014 Feb; 7():61. PubMed ID: 24507702
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In Silico Design of Recombinant Chimera T Cell Peptide Epitope Vaccines for Visceral Leishmaniasis.
    Machado AS; Martins VT; Humbert MV; Christodoulides M; Coelho EAF
    Methods Mol Biol; 2022; 2410():463-480. PubMed ID: 34914063
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
    Fernandes AP; Coelho EA; Machado-Coelho GL; Grimaldi G; Gazzinelli RT
    Curr Opin Microbiol; 2012 Aug; 15(4):476-85. PubMed ID: 22698479
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Visceral leishmaniasis: A novel nuclear envelope protein 'nucleoporins-93 (NUP-93)' from Leishmania donovani prompts macrophage signaling for T-cell activation towards host protective immune response.
    Singh MK; Jamal F; Dubey AK; Shivam P; Kumari S; Pushpanjali ; Bordoloi C; Narayan S; Das VNR; Pandey K; Das P; Singh SK
    Cytokine; 2019 Jan; 113():200-215. PubMed ID: 30001865
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.
    Gupta R; Kumar V; Kushawaha PK; Tripathi CP; Joshi S; Sahasrabuddhe AA; Mitra K; Sundar S; Siddiqi MI; Dube A
    PLoS One; 2014; 9(1):e86073. PubMed ID: 24475071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recovery of antigen-specific T cell responses from dogs infected with Leishmania (L.) infantum by use of vaccine associated TLR-agonist adjuvant.
    Schaut RG; Grinnage-Pulley TL; Esch KJ; Toepp AJ; Duthie MS; Howard RF; Reed SG; Petersen CA
    Vaccine; 2016 Oct; 34(44):5225-5234. PubMed ID: 27665354
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effective immunotherapy against canine visceral leishmaniasis with the FML-vaccine.
    Borja-Cabrera GP; Cruz Mendes A; Paraguai de Souza E; Hashimoto Okada LY; de A Trivellato FA; Kawasaki JK; Costa AC; Reis AB; Genaro O; Batista LM; Palatnik M; Palatnik-de-Sousa CB
    Vaccine; 2004 Jun; 22(17-18):2234-43. PubMed ID: 15149782
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mimotope-based vaccines of Leishmania infantum antigens and their protective efficacy against visceral leishmaniasis.
    Costa LE; Goulart LR; Pereira NC; Lima MI; Duarte MC; Martins VT; Lage PS; Menezes-Souza D; Ribeiro TG; Melo MN; Fernandes AP; Soto M; Tavares CA; Chávez-Fumagalli MA; Coelho EA
    PLoS One; 2014; 9(10):e110014. PubMed ID: 25333662
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
    Saraiva EM; de Figueiredo Barbosa A; Santos FN; Borja-Cabrera GP; Nico D; Souza LO; de Oliveira Mendes-Aguiar C; de Souza EP; Fampa P; Parra LE; Menz I; Dias JG; de Oliveira SM; Palatnik-de-Sousa CB
    Vaccine; 2006 Mar; 24(13):2423-31. PubMed ID: 16386824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. T-cell-derived cytokines, nitric oxide production by peripheral blood monocytes and seric anti-Leishmania (Leishmania) chagasi IgG subclass patterns following immunization against canine visceral leishmaniasis using Leishvaccine and Leishmune.
    Araújo MS; de Andrade RA; Sathler-Avelar R; Teixeira-Carvalho A; Andrade MC; Vianna LR; Mayrink W; Reis AB; Malaquias LC; Mello MN; Martins-Filho OA
    Vaccine; 2009 Feb; 27(7):1008-17. PubMed ID: 19110023
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety trial using the Leishmune vaccine against canine visceral leishmaniasis in Brazil.
    Parra LE; Borja-Cabrera GP; Santos FN; Souza LO; Palatnik-de-Sousa CB; Menz I
    Vaccine; 2007 Mar; 25(12):2180-6. PubMed ID: 17239495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
    Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
    Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Immunoprophylaxis using polypeptide chimera vaccines plus adjuvant system promote Th1 response controlling the spleen parasitism in hamster model of visceral leishmaniasis.
    Gusmão MR; Ostolin TLVDP; Carvalho LM; Costa AFP; Moreira GJL; Cardoso JMO; Aguiar-Soares RDO; Reis AB; de Brito RCF; Roatt BM
    Vaccine; 2022 Sep; 40(37):5494-5503. PubMed ID: 35963820
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recombinant NAD-dependent SIR-2 protein of Leishmania donovani: immunobiochemical characterization as a potential vaccine against visceral leishmaniasis.
    Baharia RK; Tandon R; Sharma T; Suthar MK; Das S; Siddiqi MI; Saxena JK; Sundar S; Dube A
    PLoS Negl Trop Dis; 2015 Mar; 9(3):e0003557. PubMed ID: 25745863
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An immunoinformatic approach driven by experimental proteomics: in silico design of a subunit candidate vaccine targeting secretory proteins of Leishmania donovani amastigotes.
    Khan MAA; Ami JQ; Faisal K; Chowdhury R; Ghosh P; Hossain F; Abd El Wahed A; Mondal D
    Parasit Vectors; 2020 Apr; 13(1):196. PubMed ID: 32295617
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Lipophosphoglycan-3 protein from Leishmania infantum chagasi plus saponin adjuvant: A new promising vaccine against visceral leishmaniasis.
    de Oliveira Emerick S; Vieira de Carvalho T; Meirelles Miranda B; Carneiro da Silva A; Viana Fialho Martins T; Licursi de Oliveira L; de Almeida Marques-da-Silva E
    Vaccine; 2021 Jan; 39(2):282-291. PubMed ID: 33309484
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The immunogenicity and protective immunity of multi-epitopes DNA prime-protein  boost vaccines encoding Amastin-Kmp-11, Kmp11-Gp63 and Amastin-Gp63 against visceral leishmaniasis.
    Zhang J; He J; Li J; Zhou Q; Chen H; Zheng Z; Chen Q; Chen D; Chen J
    PLoS One; 2020; 15(3):e0230381. PubMed ID: 32176727
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides.
    Agallou M; Pantazi E; Tsiftsaki E; Toubanaki DK; Gaitanaki C; Smirlis D; Karagouni E
    Mol Immunol; 2018 Nov; 103():7-20. PubMed ID: 30173073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Vaccine potential of HLA-A2 epitopes from Leishmania Cysteine Protease Type III (CPC).
    Dikhit MR; Amit A; Singh AK; Kumar A; Mansuri R; Sinha S; Topno RK; Mishra R; Das VNR; Pandey K; Sahoo GC; Ali V; Bimal S; Das P
    Parasite Immunol; 2017 Sep; 39(9):. PubMed ID: 28665520
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 115 kDa serine protease confers sustained protection to visceral leishmaniasis caused by Leishmania donovani via IFN-γ induced down-regulation of TNF-α mediated MMP-9 activity.
    Choudhury R; Das P; De T; Chakraborti T
    Immunobiology; 2013 Jan; 218(1):114-26. PubMed ID: 22440312
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.